SEC Filing Analysis: Stoke Therapeutics, Inc.

Executive Summary

• Trading Significance: Low
• Key Takeaway: An officer of Stoke Therapeutics has filed a notice of a proposed sale of approximately $178k worth of common stock under a pre-arranged 10b5-1 trading plan.
• Market Impact: Minimal market impact is expected due to the small size of the transaction relative to the company's market capitalization and the pre-planned nature of the sale.

Company Information

Field	Value
Company	Stoke Therapeutics, Inc.
Ticker Symbol	null
CIK	0001623526
Industry	PHARMACEUTICAL PREPARATIONS

Insider Information

Field	Value
Name	BARUCH TICHO
CIK	0001780088
Title/Position	null
Relationship	Officer

Transaction Details

Field	Value
Form Type	144
Transaction Date	2025-11-03
Transaction Code	null
Security Type	Common Stock
Shares Involved	5,931
Price Per Share	30.04
Total Value	178167.24
Shares Owned After	null
Ownership Type	null

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$178,167.24
% of Market Cap	0.011%
Shares Transacted	5,931
% of Shares Outstanding	0.011%
Post-Transaction Ownership	Not Available
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The $178k transaction is immaterial for a company with a market capitalization of $1.65 billion.
• Ownership Concentration: Post-transaction ownership details are not provided in a Form 144, but the size of the sale is too small to meaningfully impact insider ownership concentration.
• Transaction Significance: The sale represents just 0.011% of the company's market cap and 0.011% of its shares outstanding, falling well below the thresholds for even moderate significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is a notice of a proposed sale, not a completed one. Its small size and pre-planned nature under a 10b5-1 plan mean it carries no new information about the company's prospects.

Volume & Sentiment

• Expected Volume Impact: Negligible. The number of shares is very small compared to typical daily trading volume.
• Sentiment Indicator: Neutral. Pre-scheduled insider sales for diversification or personal financial planning are common and do not typically influence market sentiment.

Additional Context

Transaction Notes

• Special Circumstances: The sale is being conducted pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2024. The filing also discloses several other small sales by the same insider in the preceding three months, establishing a pattern of routine, planned dispositions.